| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
|
N Engl J Med
|
2006
|
25.67
|
|
2
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Cancer Discov
|
2011
|
7.57
|
|
3
|
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
|
J Clin Oncol
|
2008
|
5.04
|
|
4
|
Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results.
|
J Clin Oncol
|
2005
|
3.12
|
|
5
|
Randomized phase III trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma.
|
J Clin Oncol
|
2012
|
3.08
|
|
6
|
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer.
|
J Clin Oncol
|
2002
|
2.51
|
|
7
|
Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer.
|
J Clin Oncol
|
2006
|
2.32
|
|
8
|
Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.
|
J Clin Oncol
|
2005
|
2.18
|
|
9
|
Durable long-term remission with chemotherapy alone for stage II to IV laryngeal cancer.
|
J Clin Oncol
|
2009
|
2.15
|
|
10
|
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
|
Cancer
|
2002
|
1.71
|
|
11
|
Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
|
J Clin Oncol
|
2007
|
1.66
|
|
12
|
Head and neck cancers.
|
J Natl Compr Canc Netw
|
2011
|
1.64
|
|
13
|
Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module.
|
Head Neck
|
2007
|
1.63
|
|
14
|
Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
|
Invest New Drugs
|
2007
|
1.53
|
|
15
|
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer.
|
J Clin Oncol
|
2003
|
1.52
|
|
16
|
Beam path toxicities to non-target structures during intensity-modulated radiation therapy for head and neck cancer.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.51
|
|
17
|
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy.
|
Clin Cancer Res
|
2004
|
1.44
|
|
18
|
Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma?
|
Cancer
|
2004
|
1.43
|
|
19
|
Sinonasal malignancies with neuroendocrine differentiation: patterns of failure according to histologic phenotype.
|
Cancer
|
2004
|
1.43
|
|
20
|
Phase I trial of oral estramustine and 3-hr infusional paclitaxel for the treatment of hormone refractory prostate cancer.
|
Cancer Invest
|
2002
|
1.40
|
|
21
|
Head and neck cancers, Version 2.2014. Clinical practice guidelines in oncology.
|
J Natl Compr Canc Netw
|
2014
|
1.39
|
|
22
|
Head and neck cancers, version 2.2013. Featured updates to the NCCN guidelines.
|
J Natl Compr Canc Netw
|
2013
|
1.35
|
|
23
|
Radiation-induced xerostomia in patients with head and neck cancer: pathogenesis, impact on quality of life, and management.
|
Head Neck
|
2004
|
1.34
|
|
24
|
Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients.
|
Am J Surg Pathol
|
2007
|
1.32
|
|
25
|
Genetic and expression analysis of HER-2 and EGFR genes in salivary duct carcinoma: empirical and therapeutic significance.
|
Clin Cancer Res
|
2010
|
1.26
|
|
26
|
Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer.
|
Head Neck
|
2004
|
1.08
|
|
27
|
Phase II trial of taxol in salivary gland malignancies (E1394): a trial of the Eastern Cooperative Oncology Group.
|
Head Neck
|
2006
|
1.07
|
|
28
|
Outcomes and patterns of care of patients with locally advanced oropharyngeal carcinoma treated in the early 21st century.
|
Radiat Oncol
|
2013
|
1.06
|
|
29
|
The M. D. Anderson symptom inventory-head and neck module, a patient-reported outcome instrument, accurately predicts the severity of radiation-induced mucositis.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.05
|
|
30
|
Prognostic factors in mucoepidermoid carcinoma of the salivary glands.
|
Cancer
|
2011
|
1.03
|
|
31
|
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
|
Mol Cancer Ther
|
2010
|
1.03
|
|
32
|
Head and neck cancers.
|
J Natl Compr Canc Netw
|
2008
|
1.01
|
|
33
|
Implications of methylation patterns of cancer genes in salivary gland tumors.
|
Clin Cancer Res
|
2006
|
1.00
|
|
34
|
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
|
Clin Cancer Res
|
2004
|
0.98
|
|
35
|
NCCN Task Force Report: mTOR inhibition in solid tumors.
|
J Natl Compr Canc Netw
|
2008
|
0.97
|
|
36
|
Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: comparison with methylation-specific PCR technique and clinical significance.
|
Clin Cancer Res
|
2008
|
0.95
|
|
37
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Clin Cancer Res
|
2013
|
0.95
|
|
38
|
Phase I/II study of docetaxel, cisplatin, and concomitant boost radiation for locally advanced squamous cell cancer of the head and neck.
|
J Clin Oncol
|
2006
|
0.94
|
|
39
|
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
|
Cancer
|
2005
|
0.92
|
|
40
|
An exploration of the pretreatment coping strategies of patients with carcinoma of the head and neck.
|
Cancer
|
2002
|
0.92
|
|
41
|
Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.91
|
|
42
|
Head and neck cancers.
|
J Natl Compr Canc Netw
|
2005
|
0.91
|
|
43
|
Intensive concurrent chemoradiotherapy for head and neck cancer with 5-Fluorouracil- and hydroxyurea-based regimens: reversing a pattern of failure.
|
Oncologist
|
2003
|
0.90
|
|
44
|
ZD1839 (Iressa) in non-small cell lung cancer.
|
Oncologist
|
2002
|
0.90
|
|
45
|
Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue cancer.
|
Head Neck
|
2009
|
0.89
|
|
46
|
Mucosal melanoma of the head and neck.
|
J Natl Compr Canc Netw
|
2012
|
0.89
|
|
47
|
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
|
Cancer
|
2003
|
0.89
|
|
48
|
Long-term functional and survival outcomes after induction chemotherapy and risk-based definitive therapy for locally advanced squamous cell carcinoma of the head and neck.
|
Head Neck
|
2013
|
0.89
|
|
49
|
MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome.
|
PLoS One
|
2013
|
0.88
|
|
50
|
The role of trastuzumab in the management of salivary ductal carcinomas.
|
Anticancer Res
|
2013
|
0.88
|
|
51
|
Neoadjuvant chemotherapy for squamous cell carcinoma of the oral tongue in young adults: a case series.
|
Head Neck
|
2005
|
0.88
|
|
52
|
Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
|
Cancer
|
2002
|
0.87
|
|
53
|
A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.
|
Am J Clin Oncol
|
2009
|
0.86
|
|
54
|
Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck.
|
Head Neck
|
2011
|
0.85
|
|
55
|
The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma: potential for decreased toxicity and combination with biological therapy.
|
Cancer
|
2002
|
0.85
|
|
56
|
Phase II study of gefitinib in patients with advanced salivary gland cancers.
|
Head Neck
|
2015
|
0.83
|
|
57
|
Videos in clinical medicine. Examination of the larynx and pharynx.
|
N Engl J Med
|
2008
|
0.83
|
|
58
|
Phase II trials of imatinib mesylate and docetaxel in patients with metastatic non-small cell lung cancer and head and neck squamous cell carcinoma.
|
J Thorac Oncol
|
2011
|
0.82
|
|
59
|
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer.
|
Clin Cancer Res
|
2003
|
0.82
|
|
60
|
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
|
Cancer
|
2010
|
0.82
|
|
61
|
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
|
Clin Lung Cancer
|
2006
|
0.82
|
|
62
|
Epidermal growth factor receptor inhibitors for treatment of orbital squamous cell carcinoma.
|
Arch Ophthalmol
|
2012
|
0.81
|
|
63
|
Cetuximab in cancers of the lung and head & neck.
|
Semin Oncol
|
2004
|
0.80
|
|
64
|
Gefitinib: current and future status in cancer therapy.
|
Clin Adv Hematol Oncol
|
2003
|
0.80
|
|
65
|
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.
|
Am J Pathol
|
2013
|
0.80
|
|
66
|
Merkel cell carcinoma of the tongue and head and neck oral mucosal sites.
|
Oral Surg Oral Med Oral Pathol Oral Radiol Endod
|
2006
|
0.80
|
|
67
|
Phase I study of celecoxib with concurrent irinotecan, Cisplatin, and radiation therapy for patients with unresectable locally advanced non-small cell lung cancer.
|
Front Oncol
|
2011
|
0.79
|
|
68
|
Phase I/II trial of vinorelbine and divided-dose carboplatin in advanced non-small cell lung cancer.
|
Lung Cancer
|
2003
|
0.78
|
|
69
|
High survival and organ function rates after primary chemoradiotherapy for intermediate-stage squamous cell carcinoma of the head and neck treated in a multicenter phase II trial.
|
J Clin Oncol
|
2006
|
0.78
|
|
70
|
Depression and Oropharynx Cancer Outcome.
|
Psychosom Med
|
2016
|
0.77
|
|
71
|
To TORS or Not to TORS: but is that the question? Comment on "transoral robotic surgery for advanced oropharyngeal carcinoma".
|
Arch Otolaryngol Head Neck Surg
|
2010
|
0.77
|
|
72
|
Residual nodal disease in patients with advanced-stage oropharyngeal squamous cell carcinoma treated with definitive radiation therapy and posttreatment neck dissection: Association with locoregional recurrence, distant metastasis, and decreased survival.
|
Head Neck
|
2012
|
0.77
|
|
73
|
Prognostic factors associated with decreased survival in patients with acinic cell carcinoma.
|
JAMA Otolaryngol Head Neck Surg
|
2013
|
0.75
|
|
74
|
Postoperative treatment intensification for improving outcome in the high-risk patient: an evolutionary process.
|
Head Neck
|
2005
|
0.75
|
|
75
|
Differential expression of p63 isotypes (DeltaN and TA) in salivary gland neoplasms: biological and diagnostic implications.
|
Hum Pathol
|
2005
|
0.75
|
|
76
|
Evaluation and management of the unknown primary carcinoma of the head and neck.
|
J Natl Compr Canc Netw
|
2008
|
0.75
|